Multiple surgical resections for progressive IDH wildtype glioblastoma—is it beneficial?
Acta Neurochirurgica · 2024
DOI: 10.1007/s00701-024-06025-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neurochirurgica, 2024. Verfasst von Susan Isabel Honeyman und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. susan.honeyman@ouh.nhs.uk. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
The role of repeat resection for recurrent glioblastoma (rGB) remains equivocal. This study aims to assess the overall survival and complications rates of single or repeat resection for rGB.
Methods
A single-centre retrospective review of all patients with IDH-wildtype glioblastoma managed surgically, between January 2014 and January 2022, was carried out. Patient survival and factors influencing prognosis were analysed, using Kaplan–Meier and Cox regression methods.
Results
Four hundred thirty-two patients were included, of whom 329 underwent single resection, 83 had two resections and 20 patients underwent three resections. Median OS (mOS) in the cohort who underwent a single operation was 13.7 months (95% CI: 12.7–14.7 months). The mOS was observed to be extended in patients who underwent second or third-time resection, at 22.9 months and 44.7 months respectively ( p < 0.001). On second operation achieving > 95% resection or residual tumour volume of < 2.25 cc was significantly associated with prolonged survival. There was no significant difference in overall complication rates between primary versus second ( p = 0.973) or third-time resections ( p = 0.312). The use of diffusion tensor imaging (DTI) guided resection was associated with reduced post-operative neurological deficit (RR 0.37, p = 0.002), as was use of intraoperative ultrasound (iUSS) (RR 0.45, p = 0.04).
Conclusions
This study demonstrates potential prolongation of survival for rGB patients undergoing repeat resection, without significant increase in complication rates with repeat resections. Achieving a more complete repeat resection improved survival. Moreover, the use of intraoperative imaging adjuncts can maximise tumour resection, whilst minimising the risk of neurological deficit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. susan.honeyman@ouh.nhs.uk.
- Department of Neurosurgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
- Nuffield Department of Surgery, University of Oxford, Oxford, UK.
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
ORCID-Profile: Susan Isabel Honeyman
Zitieren
APA
Honeyman, S. I., Owen, W. J., Mier, J., Marks, K., Dassanyake, S. N., Wood, M. J., Fairhead, R., Martinez-Soler, P., Jasem, H., Yarlagadda, A., Roach, J. R., Boukas, A., Stacey, R., Apostolopoulos, V., & Plaha, P. (2024). Multiple surgical resections for progressive IDH wildtype glioblastoma—is it beneficial?. Acta Neurochirurgica. https://doi.org/10.1007/s00701-024-06025-x
Vancouver
Honeyman SI, Owen WJ, Mier J, Marks K, Dassanyake SN, Wood MJ, et al. Multiple surgical resections for progressive IDH wildtype glioblastoma—is it beneficial?. Acta Neurochirurgica. 2024. doi:10.1007/s00701-024-06025-x
BibTeX
@article{Honeyman2024,
author = {Honeyman, Susan Isabel and Owen, William J and Mier, Juan and Marks, Katya and Dassanyake, Sohani N and Wood, Matthew J and Fairhead, Rory and Martinez-Soler, Pablo and Jasem, Hussain and Yarlagadda, Ananya and Roach, Joy R and Boukas, Alexandros and Stacey, Richard and Apostolopoulos, Vasileios and Plaha, Puneet},
title = {Multiple surgical resections for progressive IDH wildtype glioblastoma—is it beneficial?},
journal = {Acta Neurochirurgica},
year = {2024},
doi = {10.1007/s00701-024-06025-x}
}
EUVIMED